

EXTRACTIVE VISIBLE SPECTROPHOTOMETRIC DETERMINATION OF RAMIPRIL IN PHARMACEUTICAL PREPARATIONS

KALYANA RAMU.B* AND RAGHUBABU.K

Department of Engineering Chemistry, AU college of Engineering, Andhra University Visakhapatnam, Andhrapradesh, India
E mail: kalyanaramubrd@gmail.com

ABSTRACT

A simple, sensitive, rapid and accurate extractive visible spectrophotometric method has been developed for the determination of Ramipril in pure and in pharmaceutical formulations. The method is based on the formation of orange red colored chloroform extractable ion-pair complex between the basic nitrogen of the drug and acidic dye Tropaeolin 000 (TPOOO) in the presence of 0.1M HCl with an absorption maximum of 489.0 nm. The conditions necessary for the assaying the drug are established. The calibration graph is linear over the concentration range of 2-10 μ g/ml. The proposed method is applied to commercial available tablets or capsules and the results are statistically compared with those obtained by the UV reference method and validated by recovery studies. The method offers the advantages of rapidity, simplicity and sensitivity and low cost and can be easily applied to resource-poor settings without the need for expensive instrumentation and reagents.

Key words: ACE inhibitor, Beer's Law, Chloroform, Extraction Spectrophotometry, Tropaeolin.

INTRODUCTION

Ramipril (RAM) (Fig.1) is highly lipophilic, long acting angiotensin-converting enzyme (ACE) inhibitor and chemically it is (2S, 3aS, 6aS)-1-[(S)-N-[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid-1-ethyl ester^[1].




Fig. 1: Showing the chemical structure of RAM

It is used in the treatment of hypertension, congestive heart failure and diabetic nephropathy with microalbuminuria. Ramipril acts as a prodrug of diacid ramiprilat. Ramipril owes its activity to ramiprilat to which it is converted after oral administration. The drug effectively reduces both supine and standing blood pressure without significant alteration in the pulse rate.

RAM is official in USP and BP^[2-3] which describes HPLC and potentiometric titration method for its assay in tablets. Literature survey revealed that several analytical techniques which include HPLC^[4-12], HPTLC^[13-14], LC-MS^[15], GC^[16-17], Voltametry^[18], Radioimmunoassay^[19], Capillary electrophoresis^[20], ion selective electrode potentiometry^[21-22], atomic absorption Spectrophotometry^[23-24], Spectrofluorometry^[25-26], visible spectrophotometric^[27-32] and UV^[33] have been reported for quantitative determination of Ramipril in biological fluids and pharmaceutical formulations.

The main purpose of the present study was to establish a relatively simple, sensitive, validated and inexpensive extractive visible spectrophotometric method for the determination of RAM in pure form and in pharmaceutical preparations, since most of the previous methods involve critical reaction conditions or tedious sample preparations and less specificity. So the authors have made some attempts in this direction and succeeded in developing a method based on the reaction between the drug and acidic dye Tropaeolin

000 in the presence of 0.1M HCl. The method can be extended for the routine quality control analysis of pharmaceutical products containing RAM.

As the extraction spectrophotometric procedures are popular for their sensitivity and selectivity in the assay of drugs, the acid dye technique^[34] was therefore, utilized in the present work for the estimation of RAM.

The present paper describes simple and sensitive extraction visible spectrophotometric method for the determination of RAM, based on its tendency to form chloroform extractable ion-association complex with acidic dye belonging to Azo (monoazo) category dye TP000 (CI No. 15510) under experimental conditions by exploiting the basic nature of the drug molecule.

MATERIALS & METHODS (EXPERIMENTAL)

A Systronics UV/Visible spectrophotometer model -2203 with 10mm matched quartz cells was used for all spectral measurements. All the chemicals used were of analytical grade. Tropaeolin 000 (Fluka, 0.2%, 5.7x10⁻³M prepared by dissolving 200mg of Tropaeolin 000 in 100ml distilled water and subsequently washed with chloroform to remove chloroform soluble impurities), 0.1M HCl (prepared by diluting 8.7ml of Con. Hydrochloric acid to 1000ml with distilled water and standardized) were prepared.

Standard solution:

The standard stock solution (1mg/ml) of RAM was prepared by dissolving 100mg of RAM initially in 10ml of 0.1M sodium hydroxide, followed by dilution to 100 ml with distilled water. The working standard solution of RAM (100 μ g/ml) was obtained by appropriately diluting the standard stock solution with the same solvent.

Sample solution:

About 20 tablets were pulverized and the powder equivalent to 100mg of RAM was weighed, dispersed in 25ml of Isopropyl alcohol, sonicated for 30 minutes and filtered through Whatman filter paper No 41. The filtrate was evaporated to dryness and the residue was dissolved as under standard solution preparation.

Assay:

Aliquots of the standard RAM solution (0.5ml-2.5ml, 100 μ g/ml) were placed in a series of 125ml separating funnels. A volume of 6.0ml of 0.1M HCl and 2.0ml of TPOOO were added. The total volume of aqueous phase in each separating funnel was adjusted to 15.0ml with distilled water. Then 10.0ml of chloroform was added to each funnel, and the contents were shaken for 2 minutes.

The two phases were allowed to separate and the absorbance of the separated chloroform layer was measured at 489.0nm (Fig. 2 showing absorption spectra) against a reagent blank within the stability period (5minutes to 1hour). The amount of drug was computed from its calibration graph (Fig-3 showing Beer's Law plot).




Fig. 2: Showing Absorption Spectra of RAM-TPOOO




Fig. 3: Showing Calibration Graph of RAM-TPOOO

RESULTS AND DISCUSSIONS

Optimum operating conditions used in the procedure were established adopting variation of one variable at a time (OVAT) method. The effect of various parameters such as time, volume and strength of TPOOO reagent, 0.1M HCl and solvent for final dilution of the colored species were studied.

The water immiscible solvents tested for the extraction of colored complex into organic phase include chlorobenzene, dichloromethane, carbon tetra chloride, benzene, n-butanol or chloroform. Chloroform was preferred for its selective extraction of colored drug -dye complex into organic layer from the aqueous phase. The stoichiometric ratio of the drug to dye was determined by the slope ratio method and was found to be 1:1.

The optical characteristics such as Beer's law limit, Sandell's sensitivity, molar absorptivity, percent relative standard deviation, (calculated from the six measurements containing 3/4th of the

amount of the upper Beer's law limits), Regression characteristics like standard deviation of slope (Sb), standard deviation of intercept (Sa), standard error of estimation (Se) and % range of error (0.05 and 0.01 confidence limits) were calculated and are shown in Table-1.

Commercial formulations containing RAM were successfully analyzed by the proposed method. The values obtained by the proposed and reference methods for formulations were compared statistically by the t- and f-test and found not to differ significantly.

As an additional demonstration of accuracy, recovery experiments were performed by adding a fixed amount of the drug to the preanalyzed formulations at three different concentration levels (50%, 75% and 100%). These results are summarized in Table-2.

CONCLUSION

The reagents utilized in the proposed method are normal cost, readily available and the procedure does not involve any critical reaction conditions or tedious sample preparation. The proposed extractive visible spectrophotometric method is validated and possesses reasonable precision, accuracy, simple, sensitive and can be used as alternative method to the reported ones for the routine determination of RAM depending on the need and situation.

Chemistry of colored species:

The positively charged aliphatic secondary nitrogen of RAM molecule in acid medium is expected to attract the negatively charged part of the acidic dye TPOOO and form an ion pair held together through electrostatic attraction. Based on the analogy, the structure of ion association complex in this method is shown in the scheme (Fig-4).

Table 1: Optical Characteristics, Precision And Accuracy Of Proposed Method.

| Parameter | Values |
|---|---------|
| λ_{max} (nm) | 489.0nm |
| Beer's law limit($\mu\text{g/ml}$) | 2 - 10 |
| Sandell's sensitivity ($\mu\text{g/cm}^2/0.001$ abs. unit) | 0.01521 |
| Molar absorptivity (Litre/mole/cm) | 27386.2 |
| Correlation Coefficient | 0.999 |
| Regression equation (Y)* | |
| Intercept (a) | +0.002 |
| Slope(b) | 0.065 |
| %RSD | 0.6502 |
| % Range of errors(95% Confidence limits) | |
| 0.05 significance level | 0.6826 |
| 0.01 significance level | 1.0704 |
| *Y = a+bx, where Y is the absorbance and x is the concentration of Ramipril in $\mu\text{g/ml}$ | |




Fig. 4: Showing scheme

Table 2: Analysis Of Ramipril By Proposed And Reference Method

| Method | *Formulations | Labeled Amount (mg) | Found by Proposed Methods | | | Found by Reference Method \pm SD | #% Recovery by Proposed Method \pm SD |
|--------|---------------|---------------------|---------------------------|-------|-------|------------------------------------|---|
| | | | **Amount found \pm SD | t | f | | |
| TPO00 | Tablet-1 | 5 | 4.947 \pm 0.0547 | 1.959 | 2.261 | 4.913 \pm 0.082 | 98.943 \pm 1.0935 |
| | Tablet-2 | 5 | 4.956 \pm 0.0279 | 2.55 | 3.432 | 4.916 \pm 0.015 | 99.125 \pm 0.5573 |

* Different batches (Tablet1 &2) from two different companies. **Average \pm Standard deviation of six determinations, the t- and f-values refer to comparison of the proposed method with reference method (UV). Theoretical values at 95% confidence limits t =2.57 and f = 5.05. # Recovery of 10mg added to the pre analyzed sample (average of three determinations). Reference method (reported UV method) using methanol (λ_{max} =218nm).

ACKNOWLEDGEMENT

One of the authors (B.Kalyana Ramu) is grateful to University Grants Commission, New Delhi, for providing financial assistance under the Teacher Fellowship. The authors are very much thankful to the Aurobindo Pharma Ltd., Hyderabad (India), for providing gift sample of the drug and convey their respectable thanks to retired Prof CSP Sastry, School of chemistry, Andhra University, for his advice and suggestions given in this work.

REFERENCES

- Franz D.N., Cardiovascular Drugs (Ed: A. R. Gennaro), in Remington: The Science and Practice of Pharmacy, 19th ed., Vol. II, Mack Publishing Company, Pennsylvania, 1995, p. 951.
- Royal Pharmaceutical Society, British Pharmacopoeia, H. M. Stationery Office, Royal Pharmaceutical Society, London, UK, 2007; vol. III: 2885-2887.
- The United States Pharmacopoeia - NF, Asian Edition, Rockville, MD; United States Pharmacopoeial Convention, Inc; 2007; Vol.3: 3101-3103.
- Belal F, Al-Zaagi IA, Gadkari EA, Abounassif MA: A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms. J Pharm Biomed Anal, 2001; 24: 335-42.
- Bhushan R, Gupta D, Singh SK: Liquid chromatographic separation and UV determination of certain antihypertensive agents. Biomedical Chromatography 2005; Vol. 20(2): 217-24.
- Bilal Yilmaz: Determination of Ramipril in pharmaceutical preparation by HPLC. Inter. J. of Pharm. Sci. Review and Res., 2010; Vol. 1(1): 39-42.
- Aboul-Enein HY, Thiffault C: Determination of Ramipril and its precursors by RP-HPLC. Anal. Lett, 1991; 24(12): 2217-2224.
- Motofumi I, Takeo K, Junichi G, Toshio N: Separation of Ramipril optical isomers by HPLC. J. Liq Chromatogr., 1990; 13(5): 991-1000.
- Rao K.V, Vijaya kumara K, Bhanuprakash I, Prabhakar G, Begum J: The determination of Ramipril in Pharmaceutical dosage forms by Reversed Phase Liquid Chromatography. Asian J Chemistry, 2006; Vol. 18: 788-92.
- Barry L. Hogan, Mark Williams, Anna Idiculla, Tarik Veysoglu and Ernest Parente: Development and validation of a LC method for the determination of the related substances of Ramipril in Altace capsules. J. Pharm. Biomed Anal. 2000; 23(4):637-651.
- Zarapakar S.S and Rane.S.H: RP-HPLC determination of ramipril and hydrochlorothiazide in tablets. Indian Drugs 2000; vol. 37: 589-593.
- Harlikar J.N and Amlani A.M: Simultaneous determination of perindopril, indapamide, ramipril, trandapril in pharmaceutical formulations using RP- HPLC. Res. J. Chem. Environ., 2003; vol. 7: 59- 62.
- Patel V.A, Patel P.G, Chaudhary B.G, Rajgor N.B, Rathi S.G: Development and validations of HPTLC method for the simultaneous estimation of Telmisartan and Ramipril in combined dosage form. International Journal on Pharmaceutical and Biological Research, 2010; Vol. 1(1): 18-24.
- Jadranka O, Diljana S, Mirjana A, Dusanka MO, Zivoslav T: Reversed-phase thin-layer chromatography of some angiotensin converting enzyme (ACE) inhibitors and their active metabolites. J Serbian Chem. Soc., 2006; 71: 621-8.
- Zhimeng Z, Andre V and Len N: Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma. J. Chromatography B., 2002; vol. 779(2): 297-306.
- Maurer H.H, Kramer T, Arlt J.W: Screening for the detection of angiotensin-converting enzyme inhibitors and their metabolites, and AT II Receptor Antagonists, Therap. Drug Monitor, 1998; 20: 706-713.
- Sereda K.M, Hardman T.C, Dilloway M.R, Lant A.F: Development of a method for the detection of Angiotensin converting enzyme inhibitors using Electron Capture-Gas Chromatography detection. Anal. Proc., 1993; 30(9): 371-372.
- Al-Majed A.A, Belal F, Abadi A, Al- Obaid A.M: The Volta metric study and determination Ramipril in dosage forms and biological fluids. Farmaco II, 2000; 55(3): 233-238.
- Eckert H.G, Muenscher G, Ockonomopulos R, Strecker H, Urbach J, Wissman H: A radioimmuno assay for the ACE inhibitor Ramipril and its active metabolite, Arzenein, Forsch./ Drug Research, 1985; Vol. 35(8): 1251-1256.
- Hillaer S, De Grauwe K and Van den Bossche W: Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis. J.Chromatogr. A 2001; vol. 924: 439- 449.
- Aboul-Enein H. Y, Stefen, R. I and Van Staden A. J. F: Analysis of several angiotensin-converting enzyme inhibitors using potentiometric, enantioselective membrane electrodes. Anal Lett., 1999; vol. 32: 623-632.
- Aboul-Enein H.Y, Bunaciu A.A, Bala C, Fleischin S: Enalapril and Ramipril selective membranes. Anal Lett. 1997; 30:1999-2008.
- Abdellatef HE, Ayad MM and Taha EA: Spectrophotometric and atomic absorption spectrophotometric determination of Ramipril and perindopril through ternary complex formation with eosin and Cu (II). J. Pharm. Biomed. Anal., 1999; Vol. 18: 1021-1027.
- Ayad MM, Shalaby AA, Abdellatef HE and Hosny MM: Spectrophotometric and AAS determination of Ramipril and enalapril through ternary complex formation. J. Pharm. Biomed. Anal., 2002; vol. 28: 311-321.
- Al-Majed A.A and Al-Zehouri J: Use of NBD-F for the determination of Ramipril in tablets and spiked human plasma. Farmaco II, 2001; Vol. 56:291-296.
- Hisham E. Abdellatef: Spectrophotometric and Spectro fluorimetric methods for the determination of Ramipril in its pure and dosage form. Spectro chimica Acta part A: Molecular and Bimolecular spectroscopy 2007; Vol. 66(3): 701-706.
- Rahman N, Ahmed Y and Azmi S.N.H: Kinetic spectrophotometric method for the determination of Ramipril in pharmaceutical formulations. A.A.P.S. Pharm. SciTech, 2005; Vol. 6: 543-551.
- Blaish S.M, Abdine H.H, El-Yazbi FA and Shaalan RA: Spectrophotometric determination of enalapril maleate and ramipril in dosage forms. Spectroscopie Lett, 2000; vol. 33: 91-102.
- Salama F.M, El-Sattar O.I.A, El-Aba Sawy NM and Fuad MM: Spectrophotometric determination of some ACE inhibitors through charge transfer complexes. Al Azhar J. Pharm Sci., 2001; vol. 27: 121- 132.
- Al-Majed A.A, Belal F and Al-Warthan AA: Spectrophotometric determination of Ramipril (a novel ACE inhibitor) in dosage forms. Spectroscopie Lett 2001; Vol. 34: 211-220.

31. Rahman N, Rahman H and Azmi S.N.H: Kinetic spectrophotometric method for the determination of Ramipril in commercial dosage forms. *International Journal of Biological and Medical Sciences*, 2007; vol.2 (1): 52-54.
32. Singhvi I and Chaturvedi S.C: Visible spectrophotometric and HPLC methods for estimation of Ramipril from capsule formulation. *Indian J Pharm. Sci.*, 2001; Vol. 1: 69-72.
33. Bankey S, Papdiy G.G, Saboo S.S, Bindaiya S, Deepti Jain, Khadbadi S.S: Simultaneous determination of Ramipril , Hydrochlorothiazide and Telmisartan by UV Spectrophotometry. *International Journal of Chem. Tech Research*, 2009; Vol. 1(2): 183-188.
34. Beckett, A.H. and Stenlake, J.B, *practical Pharmaceutical chemistry*, Vol. II, IV edition, CBS Publishers, New Delhi, 1997, 304.